Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Zscaler emerged from its fiscal Q1 2027 earnings print with a wave of analyst upgrades and target raises pushing the stock 7% higher on the week, making the Street's reaction, not the positioning, the story worth watching.
The analyst response to the print was unusually coordinated. At least ten firms raised their price targets on October 7 alone, all maintaining positive ratings. Wells Fargo lifted to $260 from $215. Jefferies moved to $250 from $220. JP Morgan raised to $245 from $215, and Citigroup's Fatima Boolani pushed to $245 from $205. Scotiabank went furthest at $255. The consensus mean now stands at $230.88 against a closing price of $212.25, implying roughly 9% further upside on the average estimate, with several targets clustering in the $245 to $265 range. This follows the previous note's observation that targets were already moving up aggressively ahead of the print. The direction has held: not one firm cut.
The bull and bear debate has crystallised around one number: the FY27 revenue growth guide. Bulls lean on ARR growth of 25% year-on-year to $3.77 billion, 115% net revenue retention held across all four quarters, and a broadening product mix, including Security for AI and Z-Flex, that reduces dependence on seat-count expansion as enterprise AI adoption accelerates. Bears note the FY27 revenue growth midpoint of 17% represents a material deceleration from FY26's roughly 25%, and that free cash flow margin fell to 7% in Q4, raising questions about how durable the margin expansion story really is. The PE multiple has expanded sharply, rising roughly 7 points over the past 30 days to 39x, and the price-to-book now sits at 8.3x. Forward EPS momentum scores well, ranking in the 87th percentile on a 90-day basis, but the EPS surprise score of 20 is notably weak, meaning the stock's beat history relative to estimates is not exceptional despite the headline numbers.
Positioning in the lending market offers little drama. Short interest is a modest 3.9% of free float, down fractionally over the week and down nearly 2% over the past month, a gradual drift lower that reflects short sellers trimming rather than building. Borrow availability is extraordinarily loose, with roughly 95 million shares available to lend against just 6.2 million shorted. Cost to borrow has edged higher over the month, up around 74%, but in absolute terms it remains negligible at 0.45%, well within the range it has occupied all year. Options positioning is similarly benign: the put/call ratio of 0.78 sits barely half a standard deviation above its 20-day average of 0.77, a long way from the defensive extremes the stock saw earlier in the year when the PCR reached 1.07.
The most notable ownership development in the 13D/G register is Vanguard's exit. Its most recent filing in March 2026 showed a move to 0% from a prior 7.18% stake. BlackRock, by contrast, filed a fresh Schedule 13G in July 2026 disclosing a 5.1% position of around 8.25 million shares. As always with these disclosures, stakes are as-last-filed around the 5% threshold, and either holder may have moved since without a further obligation to file. On the insider front, CFO Kevin Rubin sold a combined total across multiple small tranches in late September under a pre-arranged 10b5-1 plan, a scheduled disposition rather than a discretionary signal. Net insider activity over 90 days runs to roughly minus $6.4 million, all plan-driven sales from the CFO.
The next scheduled earnings event is November 25. Between now and then, the key question is whether the FY27 deceleration story takes hold in the data or whether the newer consumption-based products sustain the growth metrics that the Street just rewarded so heavily with target raises.
See the live data behind this article on ORTEX.
Open ZS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
